ImageneBio, Inc. — Director's Dealing 2021

Nov 24, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Ikena Oncology, Inc. (IKNA)
CIK: 0001835579
Period of Report: 2021-11-22

Reporting Person: Zhang Xiaoyan Michelle (Chief Scientific Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-22	Stock Option (Right to Buy)	$13.75	A	176699	Acquired	2031-11-21	Common Stock (176699)	Direct

Footnotes

F1: 25% of the shares subject to this option shall vest and become exercisable on November 22, 2022, with the remainder vesting in 36 equal monthly installments thereafter.